SMNR (Semnur Pharmaceuticals) Other Stockholders Equity: $-0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SMNR Semnur Pharmaceuticals Inc SMNR
8 GF Score
Price $0.72
View Full Analysis

What is Semnur Pharmaceuticals Other Stockholders Equity?

Semnur Pharmaceuticals SMNR +1.41% 8 Other Stockholders Equity is $-0.00 Mil as of Mar. 2026. GuruFocus rates SMNR with a GF Score™ of 8/100.

Semnur Pharmaceuticals's Other Stockholders Equity for the quarter that ended in Mar. 2026 was $-0.00 Mil.

Semnur Pharmaceuticals's quarterly Other Stockholders Equity increased from Sep. 2025 ($-0.00 Mil) to Dec. 2025 ($0.00 Mil) but then declined from Dec. 2025 ($0.00 Mil) to Mar. 2026 ($-0.00 Mil).

Semnur Pharmaceuticals's annual Other Stockholders Equity stayed the same from Dec. 2023 ($0.00 Mil) to Dec. 2024 ($0.00 Mil) but then declined from Dec. 2024 ($0.00 Mil) to Dec. 2025 ($0.00 Mil).

Semnur Pharmaceuticals Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Semnur Pharmaceuticals's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Semnur Pharmaceuticals Other Stockholders Equity Chart

Semnur Pharmaceuticals Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
0.00 0.00 0.00 0.00

Semnur Pharmaceuticals Quarterly Data
Dec22 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 -0.00 0.00 -0.00
SMNR
8GF Score
Semnur Pharmaceuticals Inc SMNR
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Semnur Pharmaceuticals Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of $-0.00 Mil mean?
Semnur Pharmaceuticals (SMNR) has a Other Stockholders Equity of $-0.00 Mil as of Mar. 2026. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Semnur Pharmaceuticals and its competitors.
Is Semnur Pharmaceuticals' Other Stockholders Equity too high?
Semnur Pharmaceuticals' current Other Stockholders Equity is $-0.00 Mil. Overall, Semnur Pharmaceuticals has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Semnur Pharmaceuticals' Other Stockholders Equity compare to CNTB and ENLV?
Semnur Pharmaceuticals' Other Stockholders Equity of $-0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Biotechnology company?
A good Other Stockholders Equity depends on the Biotechnology industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Semnur Pharmaceuticals and its competitors. Semnur Pharmaceuticals's current Other Stockholders Equity is $-0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Semnur Pharmaceuticals stock overvalued right now?
Semnur Pharmaceuticals (SMNR) has a current Other Stockholders Equity of $-0.00 Mil. The current Other Stockholders Equity is $-0.00 Mil. Semnur Pharmaceuticals' overall GF Score™ is 8/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Semnur Pharmaceuticals (SMNR), the current Other Stockholders Equity is $-0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Semnur Pharmaceuticals Business Description

Address 960 San Antonio Road, Palo Alto, CA, USA, 94303
Semnur Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its main product candidate, SP-102 (10 mg, dexamethasone sodium phosphate viscous gel), is being developed as a non-opioid novel injectable corticosteroid gel formulation for patients with moderate to severe LRP (also known as sciatica), containing no preservatives, surfactants, solvents, or particulates.
8GF Score

Get the complete analysis for SMNR

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.72
Price